18F-FDG-PET/CT in evaluating response to therapy in solid tumors: Where we are and where we can go

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 6, 2011, Pages 620-632

  Herrmann, K ^a   Benz, M R ^a   Krause, B J ^b   Pomykala, K L ^a   Buck, A K ^c   Czernin, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Outcome assessment; Positron emission tomography; Therapy response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; IMATINIB; SUNITINIB;

ADJUVANT CHEMORADIOTHERAPY; BREAST CANCER; CANCER SIZE; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG UPTAKE; ESOPHAGUS CANCER; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GLUCOSE UTILIZATION; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REPRODUCIBILITY; REVIEW; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH CANCER; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

FLUORODEOXYGLUCOSE F18; HUMANS; MOLECULAR IMAGING; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84857598657     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Boellaard R. Methodological aspects of multicenter studies with quantitative PET. Methods Mol Biol 2011;727:335-49.
2. Herrmann K, Krause BJ, Bundschuh RA et al.: Monitoring response to therapeutic interventions in patients with cancer. Semin Nucl Med 2009;39:210-32.
3. Herrmann K, Walch A, Balluff B, Tänzer M, Höfler H, Krause BJ et al. Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. Nature clinical practice. Gastroenterology & Hepatology 2009;6:170-83.
4. Weber WA, Figlin R: Monitoring cancer treatment with PET/CT: does it make a difference? Journal of nuclear medicine: official publication. Society of Nuclear Medicine 2007;48(Suppl 1):36S-44S.
5. Weber WA, Wieder H. Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging 2006;33(Suppl 1):27-37.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14. (Pubitemid 11167383)
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
8. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited, a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
10. Guay C, Lépine M, Verreault J, Bénard F. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003;44:1225-31. (Pubitemid 39655181)
11. Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33. (Pubitemid 29323856)
12. Zinzani PL, Magagnoli M, Chierichetti F, Zompatori M, Garraffa G, Bendandi M et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-4. (Pubitemid 29533567)
13. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976;38:388-94.
14. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21:2574-82. (Pubitemid 46606340)
15. Suzuki C, Blomqvist L, Sundin A, Jacobsson H, Byström P, Berglund A et al. The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 2011 [Epub ahead of print].
16. Veit-Haibach P, Schaefer NG, Steinen HC, Soyka JD, Seifert B, Stahel RA. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 2010;67:311-7.
17. Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C et al. Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2011 [Epub ahead of print].
18. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D et al. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2009;15:2856-63.
19. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD et al. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 2008;14:715-20. (Pubitemid 351231152)
20. Beer AJ, Wieder HA, Lordick F, Ott K, Fischer M, Becker K et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology 2006;239:472-80.
21. der HA, Beer AJ, Lordick F, Ott K, Fischer M, Rummeny EJ et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. Journal of nuclear medicine: official publication. Society of Nuclear Medicine 2005;46:2029-34.
22. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with nonsmall-cell lung cancer. J Clin Oncol 2003;21:1285-92. (Pubitemid 46606405)
23. Weber WA, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003;21:2651-7. (Pubitemid 46606307)
24. r WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-7.
25. Schwartz J, Humm JL, Gonen M, Kalaigian H, Schoder H, Larson SM et al. Repeatability of SUV measurements in serial PET. Med Phys 2011;38:2629-38.
26. Herrmann K, Bundschuh RA, Rosenberg R, Schmidt S, Praus C, Souvatzoglou M et al. Comparison of different SUV-based meth-ods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI. Mol Imaging Biol 2011;13:1011-9.
27. Rosenberg R, Herrmann K, Gertler R, Künzli B, Essler M, Lordick F et al. The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. Int J Colorectal Dis 2009;24:191-200.
28. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82 (Pubitemid 29512308)
29. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-50S.
30. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multicentre trials. Eur J Nucl Med Mol Imaging 2008;35:2320-33.
31. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005;106:1376-81. (Pubitemid 41129604)
32. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52-9. (Pubitemid 43053523)
33. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2Kleoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005;23:8362-70.
34. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805. (Pubitemid 47308659)
35. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65. (Pubitemid 32565444)
36. Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004;22:900-8. (Pubitemid 41103602)
37. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-10. (Pubitemid 46594034)
38. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008;14:2012-8. (Pubitemid 351551110)
39. cini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. Journal of nuclear medicine: official publication. Society of Nuclear Medicine 2006;47:1241-8.
40. Dose Schwarz J, Bader M, Jenicke L, Hemminger G, Jänicke F, Avril N. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 2005;46:1144-50. (Pubitemid 43741076)
41. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95. (Pubitemid 30220547)
42. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88. (Pubitemid 30220546)
43. Strobel K, Dummer R, Steinen HC, Conzett KB, Schad K, Lago MP et al. Chemotherapy response assessment in stage IV melanoma patients-comparison of 18F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. Eur J Nucl Med Mol Imaging 2008;35:1786-95.
44. Avril N, Sassen S, Schmalfeldt B, Naehrig J, Rutke S, Weber WA et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol 2005;23:7445-53. (Pubitemid 46291806)
45. Brun E, Kjellén E, Tennvall J, Ohlsson T, Sandell A, Perfekt R et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002;24:127-35. (Pubitemid 34111509)
46. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25:1753-9. (Pubitemid 46797957)
47. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32:153-62. (Pubitemid 40248485)
48. Stroobants S, Verschakelen J, Vansteenkiste J. Value of FDG-PET in the management of non-small cell lung cancer. Eur J Radiol 2003;45:49-59. (Pubitemid 36020310)
49. Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU 3rd et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828-34. (Pubitemid 46211529)
50. Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339-48. (Pubitemid 40129294)
51. Reynoso D, Subbiah V, Trent JC, Guadagnolo BA, Lazar AJ, Benjamin R et al. Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol 2010;101:327-33.
52. Collin C, Godbold J, Hajdu S, Brennan M. Localized extremity soft tissue sarcoma: an analysis of factors affecting survival. J Clin Oncol 1987;5:601-12. (Pubitemid 17062498)
53. Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shiu M et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults. J Clin Oncol 1992;10:1317-29.
54. Ambrosini V, Nicolini S, Caroli P, Nanni C, Massaro A, Marzola MC et al. PET/CT imaging in different types of lung cancer: An overview. Eur J Radiol 2011 [Epub ahead of print].
55. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500-7. (Pubitemid 36706537)
56. Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 2009;151:221-8.
57. Schreyögg J, Weller J, Stargardt T, Herrmann K, Bluemel C, Dechow T et al. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer. J Nucl Med 2010;51:1668-75.
58. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 2009;361:32-9.
59. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93-
60. Hicks RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med 2009;50(Suppl 1):31S-42S.
61. Aukema TS, Kappers I, Olmos RA, Codrington HE, van Tinteren H, van Pel R et al. Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer? J Nucl Med 2010;51:1344-8.
62. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients widi non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011;17:3304-15.
63. Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M et al. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol 2011;29:1701-8.
64. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R et al. 18F-FDG-PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011;52:1684-9.
65. ik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M et al. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus. J Nucl Med 2010;51:1863-9.
66. Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer 2006;95:1174-9. (Pubitemid 44658480)
67. Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP et al. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. Ann Surg 2009;250:888-94.
68. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-8. (Pubitemid 46646244)
69. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M et al. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 2007;48:1945-50. (Pubitemid 350232302)
70. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA et al. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 2011;18:3316-23.
71. Vallböhmer D, Hölscher AH, Schneider PM, Schmidt M, Dietlein M, Bollschweiler E et al. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 2010;102:135-40.
72. Lambrecht M, Deroose C, Roels S, Vandecaveye V, Penninckx F, Sagaert X et al. The use of FDG-PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol 2010;49:956-63.
73. Janssen MH, Ollers MC, Riedl RG, van den Bogaard J, Buijsen J, van Stiphout RG et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F- fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys 2010;77:392-9.
74. Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27:535-41.
75. Martoni AA, Zamagni C, Quercia S, Rosati M, Cacciari N, Bernardi A et al. Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy. Cancer 2010;116:805-13.
76. Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC cancer 2011;11:452.
77. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 2007;189:W324-30.
78. Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J et al. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol 2009;27:439-45.
79. zum Buschenfelde CM, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011;52:1189-96.
80. van Heijl M, Omloo JM, van Berge Henegouwen MI, Henegouwen MI, Busch OR, Tilanus HW, Bossuyt PM et al. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). BMC Med Phys 2008;8:3.
81. Cashen AF, Dehdashti F, Luo J, Homb A, Siegel BA, Bartlett NL. 18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation. J Nucl Med 2011;52:386-92.
82. Markova J, Kahraman D, Kobe C. Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leukemia & lymphoma 2011 [In press].
83. Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2008;62:55-61.
84. Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol 2008;26:4610-6.
85. Zhang HQ, Yu JM, Meng X, Yue JB, Feng R, Ma L. Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy Eur J Radiol 2011;77:92-6.
86. Guerra L, Niespolo R, Di Pisa G, Ippolito D, De Ponti E, Terrevazzi S et al. Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. Abdom Imaging 2011;36:38-45.